Panacea Biotec Past Earnings Performance
Past criteria checks 0/6
Panacea Biotec has been growing earnings at an average annual rate of 37%, while the Biotechs industry saw earnings growing at 12% annually. Revenues have been growing at an average rate of 0.5% per year.
Key information
37.0%
Earnings growth rate
37.1%
EPS growth rate
| Biotechs Industry Growth | 5.1% |
| Revenue growth rate | 0.5% |
| Return on equity | -1.4% |
| Net Margin | -2.1% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Panacea Biotec makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 5,516 | -117 | 1,635 | 0 |
| 30 Sep 23 | 5,163 | 99 | 1,579 | 0 |
| 30 Jun 23 | 4,784 | 334 | 1,304 | 0 |
| 31 Mar 23 | 4,599 | -332 | 1,483 | 0 |
| 31 Dec 22 | 4,718 | 12,164 | 1,692 | 0 |
| 30 Sep 22 | 5,124 | 11,478 | 1,828 | 0 |
| 30 Jun 22 | 6,395 | 10,791 | 1,706 | 0 |
| 31 Mar 22 | 6,612 | 10,783 | 2,050 | 0 |
| 31 Dec 21 | 6,888 | -2,137 | 2,014 | 0 |
| 30 Sep 21 | 6,746 | -2,046 | 1,949 | 0 |
| 30 Jun 21 | 6,245 | -1,704 | 1,655 | 0 |
| 31 Mar 21 | 6,248 | -1,462 | 1,774 | 0 |
| 31 Dec 20 | 5,819 | -1,604 | 1,724 | 0 |
| 30 Sep 20 | 6,079 | -1,405 | 1,474 | 0 |
| 30 Jun 20 | 5,510 | -1,945 | 1,453 | 0 |
| 31 Mar 20 | 5,441 | -1,878 | 1,649 | 0 |
| 31 Dec 19 | 5,454 | 653 | 1,573 | 0 |
| 30 Sep 19 | 4,880 | 715 | 1,521 | 0 |
| 30 Jun 19 | 4,832 | 482 | 1,396 | 0 |
| 31 Mar 19 | 4,567 | 410 | 1,620 | 0 |
| 31 Mar 18 | 5,928 | -716 | 1,712 | 0 |
| 31 Mar 17 | 5,440 | -392 | 1,797 | 0 |
| 31 Mar 16 | 6,531 | -183 | 1,708 | 0 |
| 31 Mar 15 | 6,872 | -1,065 | 1,668 | 0 |
| 31 Mar 14 | 5,100 | -1,121 | 2,661 | 0 |
Quality Earnings: 531349 is currently unprofitable.
Growing Profit Margin: 531349 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 531349 is unprofitable, but has reduced losses over the past 5 years at a rate of 37% per year.
Accelerating Growth: Unable to compare 531349's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 531349 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.3%).
Return on Equity
High ROE: 531349 has a negative Return on Equity (-1.44%), as it is currently unprofitable.